Glomerular filtration rate is an independent prognostic factor in patients with B-large cell lymphoma

Znanstveni rad - Izvorni znanstveni rad

• Autor: Vedran Premužić
• Autor: Sandra Bašić-Kinda
• Autor: Ivo Radman
• Autor: Dino Dujmović
• Autor: Ivana Ilić
• Autor: Neno Živković
• Autor: Lucija Maleta
• Autor: Marko Kralik
• Autor: Margareta Dobrenić
• Autor: Lea Galunić-Bilić
• Autor: Pavle Rončević
• Autor: Marijo Vodanović
• Autor: Igor Aurer
• Autorova ustanova: Sveučilište u Zagrebu; Medicinski fakultet; (KATEDRA ZA INTERNU MEDICINU)
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Kliničke medicinske znanosti; Interna medicina

Sažetak (engleski)

Chronic kidney dysfunction is associated with increased mortality in multiple cancer types. Preliminary evidence suggests the same to be true for B-large cell lymphomas (B-LCL). To analyze the relationship of glomerular filtration rate (GFR) and outcome of B-LCL in detail we collected data on outcomes of 285 consecutive patients with newly diagnosed B-LCL treated at our institution with standard rituximab-containing regimens who did not have preexisting kidney disease or urinary tract obstruction at presentation. Median age was 59, range 18 to 87, 145 were male and 140 females. Forty-four had GFR < 60 mL/min, 123 had 60 to 90 mL/min, and 118 > 90 mL/min. Median follow-up of surviving patients was 49 months and estimated 3-year survival 76%. In univariate analysis age (P < .001), GFR (P = .014), stage (P < .001), performance status (P = .044), chemotherapy regimen (P < .01), and international prognostic index (IPI) (P < .001) were statistically significant prognostic factors. In multivariate analysis, age and GFR remained the only independent prognostic factors. Subtracting 1 from the IPI score of patients who had GFR > 90 mL/min and IPI > 1 resulted in a prognostic index that divides patients into 3 prognostic groups (low risk = 0-1, intermediate risk = 2-3 and high risk = 4-5) with an acceptable patient distribution frequency (38%, 39%, and 23%, respectively) and improved statistical significance and separation in comparison to IPI (5-year survival rates of 92%, 74%, and 42%, respectively). GFR is an important independent prognostic factor for B-LCL that should be taken into account in clinical decision making and data analysis and probably be incorporated in prognostic indices.

• Ključne riječi (engleski): Antineoplastic Combined Chemotherapy Protocols / therapeutic use; Female; Glomerular Filtration Rate; Humans; Lymphoma, Large B-Cell, Diffuse / drug therapy; Lymphoma, Non-Hodgkin / pathology; Male; Middle Aged; Prognosis; Retrospective Studies; Rituximab / therapeutic use; Survival Rate
• Jezik: engleski
• Vrsta publikacije: Znanstveni rad - Izvorni znanstveni rad
• Status objave: Objavljen
• Vrsta recenzije: Recenziran
• Verzija publikacije: Objavljena verzija rada (izdavačev PDF)
• Naslov časopisa: Medicine
• Brojčani podaci: vol. 102, br. 20, e33675
• p-ISSN: 0025-7974
• DOI: https://doi.org/10.1097/MD.0000000000033675
• URN:NBN: urn:nbn:hr:105:817362
• Datum objave publikacije: 2023-05-19
• URL dokumenta: https://journals.lww.com/10.1097/MD.0000000000033675
• Vrsta resursa: Tekst
• Prava pristupa: Otvoreni pristup
• Datum i vrijeme pohrane: 2023-09-28 07:15:06